Alembic Pharmaceuticals reported a consolidated net profit of ₹173 crore for the quarter ended June 30, 2026, marking a 12.1% increase from ₹154.38 crore in the corresponding period of the previous year. The company’s revenue from operations grew to ₹2,150 crore, up 26% year-on-year, driven primarily by a 49% surge in its US formulation business. This performance underscores the company’s expanding global footprint and operational efficiency during the initial quarter of FY27, with broad-based growth across all key segments.

Consolidated Financial Performance

The Board of Directors approved the unaudited consolidated financial results on August 4, 2026. Statutory auditors KKC & Associates LLP issued an unqualified review report on the statements. Key consolidated metrics for the quarter are detailed below:

*Note: Previous year EBITDA Pre-R&D derived from current year growth rate and reported figure.

EBITDA pre-R&D increased to ₹523 crore, representing a margin of 24%. Regulatory disclosures under Regulation 52(4) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, were included in the filing.

Segment-Wise Revenue Breakdown

The investor presentation highlighted strong growth across all business verticals. The US Formulation segment emerged as the primary growth driver, with revenues jumping to ₹778 crore from ₹523 crore in Q1FY26. This was supported by seven new product launches and volume gains. The API segment also showed robust health, growing 33% year-on-year to ₹346 crore, backed by a strong order book. India Branded Business grew 7% to ₹642 crore, while Ex-US Formulation rose 17% to ₹383 crore.

Management Commentary and Pipeline

Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited, stated that the company started FY27 on a strong note with broad-based growth across businesses. He attributed the performance to healthy volume growth, successful new product launches, and continued execution across key markets. Amin noted that the US business delivered strong momentum while other markets recorded steady growth. The company remains focused on strengthening its product portfolio and advancing its pipeline.

In the US market, Alembic launched seven new products in Q1FY27, bringing the total commercialized portfolio to 185 products. The company received 10 ANDA approvals during the quarter and has 244 approved ANDAs in total, including 20 tentative approvals. A pipeline of 15+ product launches is expected in FY27. R&D spending increased 29% year-on-year to ₹1.86 billion, representing 9% of revenue, focusing on peptide development and complex platforms.

Standalone Results and Balance Sheet Health

On a standalone basis, Alembic Pharmaceuticals reported a net profit of ₹196.96 crore for Q1FY27, a substantial rise from ₹103.52 crore in Q1FY26. Standalone revenue reached ₹1,868.06 crore, up from ₹1,494.17 crore in the same quarter last year. The standalone operating margin expanded to 19.26% from 14.83% year-on-year, indicating improved cost management at the parent company level.

The company’s balance sheet remains robust with a debt-equity ratio of 0.28 times for the consolidated entity and 0.22 times for the standalone entity. Net worth increased to ₹5,856.21 crore (consolidated) and ₹5,819.40 crore (standalone). The current ratio was maintained at 1.69 times (consolidated) and 1.75 times (standalone), reflecting healthy liquidity positions.

Alembic Pharmaceuticals has announced plans to introduce more than 15 new products in the United States by FY27. The development underscores the company's continued focus on strengthening its footprint in the U.S. pharmaceutical market, which remains a key geography for Indian generic drug manufacturers.

U.S. Market Expansion Plans

The company's pipeline targets the introduction of over 15 new products in the U.S. by FY27. The following table summarizes the key details of the announced expansion plan:

Alembic Pharmaceuticals' plan to launch more than 15 new products in the U.S. by FY27 highlights the company's commitment to growing its international generics business. The U.S. remains a critical market for Indian pharmaceutical companies, given its scale and demand for affordable generic medicines.